Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

994 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinicopathologic Features and Efficacy of Induction Chemotherapy in Nasopharyngeal Carcinoma: Real-World Experience.
Majidova N, Sarı M, Kahvecioglu FA, Ozcan E, Akdag MO, Dogan A, Yıldırım S, Sonusen SD, Yunusov E, Yasar A, Celebi A, Sever N, Kocaaslan E, Erel P, Agyol Y, Guren AK, Arıkan R, Isık S, Balvan O, Geredelı C, Uygun K, Hacibekiroglu I, Kostek O, Bayoglu IV. Majidova N, et al. Among authors: yildirim s. Oncol Res Treat. 2024 Apr 2:1-7. doi: 10.1159/000537988. Online ahead of print. Oncol Res Treat. 2024. PMID: 38565096
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.
Kahraman S, Karakaya S, Kaplan MA, Goksu SS, Ozturk A, Isleyen ZS, Hamdard J, Yildirim S, Dogan T, Isik S, Celebi A, Gulbagci BB, Paksoy N, Dogan M, Turk HM, Bilici A, Tatli AM, Akbas S, Turan N, Hacibekiroglu I, Dogu GG, Aydiner A, Sumbul AT, Akyurek S, Yalciner M, Demirkazik A, Gursoy P, Aykan MB, Sahin E, Karadag İ, Kostek O, Er MM, Artaç M, Duzkopru Y, Aydin D, Isik D, Karakas Y, Kilickap S, Erol C, Demir B, Civelek B, Ergun Y, Akinci MB, Dogan I, Karadurmus N, Yumuk PF, Sendur MAN. Kahraman S, et al. Among authors: yildirim s. Sci Rep. 2024 Mar 9;14(1):5820. doi: 10.1038/s41598-024-56046-w. Sci Rep. 2024. PMID: 38461209 Free PMC article.
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.
Yildirim S, Dogan A, Akdag G, Yüksel Yasar Z, Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS, Alan O, Coban Kokten S, Isik D, Surmeli H, Basoglu T, Sever ON, Odabas H, Yildirim ME, Turan N. Yildirim S, et al. Sci Rep. 2024 May 27;14(1):12123. doi: 10.1038/s41598-024-63096-7. Sci Rep. 2024. PMID: 38802494 Free PMC article.
Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.
Akdag G, Yildirim S, Dogan A, Yuksel Yasar Z, Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS, Turkoglu E, Alan O, Coban Kokten S, Isik D, Sever ON, Odabas H, Yildirim ME, Turan N. Akdag G, et al. Among authors: yildirim s, yildirim me. Chemotherapy. 2024 Feb 16. doi: 10.1159/000537874. Online ahead of print. Chemotherapy. 2024. PMID: 38368871
The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer.
Çetin K, Kökten Ş, Sarıkamış B, Yıldırım S, Gökçe ON, Barışık NÖ, Kılıç Ü. Çetin K, et al. Among authors: yildirim s. Breast Cancer Res Treat. 2024 May;205(1):17-27. doi: 10.1007/s10549-023-07242-1. Epub 2024 Jan 25. Breast Cancer Res Treat. 2024. PMID: 38273215 Free PMC article.
994 results